circana glp 1 GLP-1 Medication Usage is Impacting the U.S. Apparel Industry GLP-1 users 'a friend' to

Sudre, C

Per the U.S

Tissue-local accumulation: BPC-157 may accumulate at injury sites or in tissues at concentrations exceeding serum levels, producing sustained local exposure despite rapid serum clearance

The information asymmetry Grey market communities often present themselves as informed, science-literate groups making rational decisions based on available data

One study I am looking forward to seeing in greater detail is SYNCHRONIZE 1, where survodutide, a glucagon/GLP 1 dual agonist being developed by Boehringer Ingelheim and Zealand Pharma, achieved 16.6% weight loss at 76 weeks compared with 3.2% for placebo

GLP-1 may also directly stimulate glucose uptake in muscle cells (22)